CL2017003228A1 - Fragmentos mutantes de proteína ras - Google Patents

Fragmentos mutantes de proteína ras

Info

Publication number
CL2017003228A1
CL2017003228A1 CL2017003228A CL2017003228A CL2017003228A1 CL 2017003228 A1 CL2017003228 A1 CL 2017003228A1 CL 2017003228 A CL2017003228 A CL 2017003228A CL 2017003228 A CL2017003228 A CL 2017003228A CL 2017003228 A1 CL2017003228 A1 CL 2017003228A1
Authority
CL
Chile
Prior art keywords
ras protein
protein mutant
mutant fragments
peptide
region
Prior art date
Application number
CL2017003228A
Other languages
English (en)
Inventor
Jon Amund Eriksen
Original Assignee
Targovax Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targovax Asa filed Critical Targovax Asa
Publication of CL2017003228A1 publication Critical patent/CL2017003228A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

<p>SE DESCRIBE UN PÉPTIDO ADECUADO PARA PRODUCIR UNA RESPUESTA INMUNE. EL PÉPTIDO CORRESPONDE A UN FRAGMENTO DE LA PROTEÍNA RAS Y COMPRENDE UNA REGIÓN DE 8 AMINOÁCIDOS LA CUAL INCLUYE UNA POSICIÓN MUTANTE DE LA PROTEÍNA RAS. LA REGIÓN TIENE AL MENOS 6 RESIDUOS DE AMINOÁCIDOS, DIFERENTES A LOS DE LA POSICIÓN MUTANTE, LOS CUALES SON IDÉNTICOS A LOS DE LA REGIÓN CORRESPONDIENTE DE LA PROTEÍNA RAS. EL PÉPTIDO TIENE UNA MUTACIÓN PUNTUAL EN EL AMINOÁCIDO QUE CORRESPONDE A LA POSICIÓN MUTANTE Y LA POSICIÓN MUTANTE ES LA POSICIÓN 146 O 117 DE LA PROTEÍNA RAS.</p>
CL2017003228A 2015-06-16 2017-12-15 Fragmentos mutantes de proteína ras CL2017003228A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15172418 2015-06-16

Publications (1)

Publication Number Publication Date
CL2017003228A1 true CL2017003228A1 (es) 2018-07-13

Family

ID=53404437

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003228A CL2017003228A1 (es) 2015-06-16 2017-12-15 Fragmentos mutantes de proteína ras

Country Status (14)

Country Link
US (1) US20190374628A1 (es)
EP (1) EP3310808A1 (es)
JP (1) JP2018518177A (es)
KR (1) KR20180021072A (es)
CN (1) CN107922472A (es)
AU (1) AU2016280770A1 (es)
BR (1) BR112017025728A2 (es)
CA (1) CA2989373A1 (es)
CL (1) CL2017003228A1 (es)
HK (1) HK1248714A1 (es)
IL (1) IL256077A (es)
MX (1) MX2017015927A (es)
RU (1) RU2018101225A (es)
WO (1) WO2016202937A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019015797A2 (pt) * 2017-02-01 2020-03-17 Modernatx, Inc. Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
WO2018145020A1 (en) * 2017-02-03 2018-08-09 The Medical College Of Wisconsin, Inc. Kras peptide vaccine compositions and method of use
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
CN112912387A (zh) * 2018-08-22 2021-06-04 弗雷德哈钦森癌症研究中心 靶向kras或her2抗原的免疫疗法
EP3914612A1 (en) 2019-01-22 2021-12-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class ii-restricted t cell receptors against ras with g12r mutation
CN110205298B (zh) * 2019-06-11 2020-05-15 焦顺昌 一种靶向kras突变的异体抗原递呈细胞、构建方法及肠癌特异性ctl细胞的制备方法
CN110172480B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 双抗原表位融合基因重组慢病毒载体、抗原提呈细胞和ctl细胞及其构建方法和应用
CN110184238A (zh) * 2019-06-11 2019-08-30 北京鼎成肽源生物技术有限公司 一种靶向kras多发突变肿瘤的特异性ctl细胞的制备方法及应用
US12453774B2 (en) 2019-11-07 2025-10-28 Genoimmune Therapeutics Co., Ltd. Tumor immunotherapy polypeptide and application thereof
CN116438308A (zh) * 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
CN116867799A (zh) * 2021-02-10 2023-10-10 上海吉倍生物技术有限公司 Ras G13D突变体表位肽及识别Ras G13D突变体的T细胞受体
EP4423256A2 (en) * 2021-10-28 2024-09-04 Genentech, Inc. Systems and methods to identify mhc-associated antigens for therapeutic intervention
CN115850377B (zh) * 2022-09-27 2026-03-20 成都朗谷生物科技股份有限公司 基于nras基因q61k突变的肿瘤新抗原多肽及其应用
WO2024147556A1 (ko) * 2023-01-05 2024-07-11 의료법인 명지의료재단 K-ras 돌연변이 다중 항원결정기 폴리펩타이드를 유효성분으로 포함하는 항암 백신용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
BRPI0709340A2 (pt) * 2006-03-27 2013-04-16 Globeimmune, Inc. mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma

Also Published As

Publication number Publication date
EP3310808A1 (en) 2018-04-25
US20190374628A1 (en) 2019-12-12
CA2989373A1 (en) 2016-12-22
MX2017015927A (es) 2018-04-18
WO2016202937A1 (en) 2016-12-22
AU2016280770A1 (en) 2018-01-04
BR112017025728A2 (pt) 2018-08-07
KR20180021072A (ko) 2018-02-28
RU2018101225A (ru) 2019-07-16
IL256077A (en) 2018-01-31
HK1248714A1 (zh) 2018-10-19
CN107922472A (zh) 2018-04-17
JP2018518177A (ja) 2018-07-12

Similar Documents

Publication Publication Date Title
CL2017003228A1 (es) Fragmentos mutantes de proteína ras
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
ZA202308519B (en) Anti-vegf protein compositions and methods for producing the same
EA202090090A1 (ru) Включение неприродных нуклеотидов и способы с ними
CY1123622T1 (el) Τροποποιημενα μηνιγγιτιδοκοκκικα fhbp πολυπεπτιδια
UY40283A (es) Método para alterar una propiedad de una planta
CY1120729T1 (el) Πεπτιδια και συνθεσεις για τη θεραπεια τραυματισμου των αρθρωσεων
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
MX2016011537A (es) Metodos y composiciones para aumentar una relacion de celulas t efectoras con respecto a las celulas t reguladoras.
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
MX387560B (es) Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
BR112017008962A2 (pt) proteínas de fusão inibidoras de c1 esterase e usos das mesmas
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
CR20180008A (es) Variantes de il-37
CL2017003144A1 (es) Péptidos lipidados resistentes a proteasas
BR112018072968A2 (pt) peptídeos monolipidados resistentes às proteases
EA201892231A1 (ru) Способ очистки белка
MX2018002616A (es) Proteina de fusion.
BR112017006969A2 (pt) peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno
NZ744289A (en) Composition containing amino acids
MX390927B (es) Partículas semejantes a virus recombinantes que utilizan la proteína gag del virus de inmunodeficiencia bovina.
MX2022000393A (es) Metodo.